Real-life experience of ledipasvir and sofosbuvir single-tablet regimen among chronic hepatitis C patients in Turkey


Yamazhan T. , Turan İ. , Ersöz G. , Günşar F. , Pullukçu H. , Danis N., ...More

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.31, pp.239-246, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 31
  • Publication Date: 2020
  • Doi Number: 10.5152/tjg.2020.19076
  • Title of Journal : TURKISH JOURNAL OF GASTROENTEROLOGY
  • Page Numbers: pp.239-246

Abstract

Background/Aims: Ledipasvir (LDV) and sofosbuvir (SOF) as single-tablet regimen (STR) has been approved for treatment of chronic HCV infection (CHC) for treatment-naive or experienced cirrhotic or non-cirrhotic patients. Our aim was to analyse the effectiveness and safety of 12-24 weeks treatment of LDV/SOF (90mg/400 mg)+/- ribavirin in a real-life setting in Turkey.